Robert Duggan
About Robert Duggan
In 2020, Robert Duggan invested $63 million in Nasdaq-listed Summit Therapeutics and became its Co-CEO, leading the biotech in developing targeted oncology therapies for difficult diagnoses.
Pharmacyclics' cancer drug Imbruvica made Duggan a billionaire in 2013 and paved the way for the company's $21 billion sale to AbbVie in 2015.
Duggan, whose son died from brain cancer, became passionate about Pharmacyclic's cancer fighting drugs and first invested in 2004.
His enthusiasm for investing began four decades earlier in a corporate finance class he took at the University of California at Santa Barbara.
In 2020, Duggan bought $63 million of shares in Nasdaq-listed Summit Therapeutics, a small biotech company, and became its CEO.
Duggan also sits on the board of Pulse Biosciences, of which he is the largest individual shareholder.
Personal stats
Citizenship
United States of AmericaSource of wealth
PharmaceuticalsResidence
Miami, FloridaMarital status
MarriedBirth date
04/28/44 (age 81)Number of children
8Education
Drop Out, University of California, Los Angeles; Drop Out, University of California, Santa BarbaraSelf-made
self-madeRobert Duggan’s fortune is worth
troy ounces of gold
median U.S. household
median U.S. income
U.S. credit card volume
GDP of the United States
United States debt
Net worth history
Annual ranking
Related people
Did you know?
Duggan is a big donor to the Church of Scientology, of which he is a member; he says he's given the church nearly $360 million over his lifetime.
Net worth over time
Real-time ranking
Financial assets
NYSE | ABBV-US
AbbVie Inc.HONG KONG | 9926-HK
Akeso IncNASDAQ | GOOGL-US
AlphabetNYSE | C-US
CitigroupNASDAQ | ISRG-US
Intuitive SurgicalNASDAQ | IOVA-US
Iovance BiotherNYSE | JPM-US
JPMorgan Chase & Co.NASDAQ | MSFT-US
MicrosoftNYSE | NEM-US
Newmont MiningNASDAQ | NVDA-US
NvidiaNASDAQ | PTGX-US
Protagonist TherapeuticsNASDAQ | PLSE-US
Pulse BioSciencesNASDAQ | RIVN-US
RivianNASDAQ | SMMT-US
Summit TherapeuticsNASDAQ | SMMT-US
Summit TherapeuticsNASDAQ | SMMT-US
Summit TherapeuticsNASDAQ | SMMT-US
Summit TherapeuticsNASDAQ | VYGR-US
Voyager TherapeuticsImages © Forbes.com. All rights reserved.